Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Govt Deregulation Panel Pushes New System to Allow Mixed Care at Patient Request
March 31, 2014
- MHLW to Set Up Study Group on Clinical Research Legislation in April: Minister Tamura
March 31, 2014
- Science Council of Japan Recommends Establishment of Clinical Research Promotion Center at PMDA
March 31, 2014
- Fulminant Hepatitis Added to Precautions Section of Package Insert for Regorafenib: MHLW Safety Information
March 31, 2014
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
- Drug-Induced Hypersensitivity Syndrome to Be Added to List of Clinically Significant Adverse Reactions for E Keppra: MHLW
March 28, 2014
- FY2014 Medical Fee Revision Expected to Shift Outpatient Care Functions from Large Hospitals to Smaller Hospitals and Clinics, Alter Patient Behavior and Prescription Patterns
March 28, 2014
- PMDA Floats New Advisory Service on Drug Makers’ Development Plans
March 27, 2014
- PMDA Announces Increase in Face-to-Face Consultation Fees in Response to Upcoming Hike in Consumption Tax
March 27, 2014
- PMDA Publishes RMP for Regpara
March 27, 2014
- Dr Tatsuya Kondo Reappointed as Chief Executive of PMDA
March 26, 2014
- MHLW Approves 37 Products, 4 New SGLT-2 Products OK’ed
March 25, 2014
- MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
- Extra Market Drug Price Survey Focal Point of Discussions towards FY2015 Tax Hike: Official
March 20, 2014
- MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
- MHLW to Draft Rules for Approval of Switch OTC Diagnostics in Meetings Open to the Public: Regulatory Reform Council
March 19, 2014
- MHLW OKs Additional Indications for Votrient, 2 Other Drugs
March 18, 2014
- FY2014 Reform to Strengthen Restrictions on Prescription of Multiple Psychotropic Drugs; Measures to Be Taken in Two Consecutive Reforms Due to Lack of Improvements
March 18, 2014
- PMDA to Up Review Fees for Generics, OTCs, Diagnostics in November
March 17, 2014
- Rules for Approval of Switch OTC Diagnostics to Be Finalized by PAFSC Committee by End of Year: PFSB Director General
March 17, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…